The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
GCLLSG 2016 | Overview of the CLLR3 trial of obinutuzumab
Clemens Wendtner, MD of Klinikum Schwabing, Munich, Germany, discusses the CLLR3 clinical trial in relapsed chronic lymphocytic leukemia (CLL). The CLLR3 trial aims to show that there is a niche for chemoimmunotherapy in late relapsed patients and answer the question of maintenance. A combination of anti-CD20 obinutuzumab with chemotherapy is used in the induction phase, with obinutuzumab alone in the maintenance phase (NCT02320383). First insights show that a combination is effective, with a potential to perform better than fludarabine, cyclophosphamide, rituximab (FCR), the gold standard in frontline CLL. Dr Wendtner hopes to prolong the remission with obinutuzumab use. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.
